Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.

MIRA Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ADVANCING TOWARD PHASE 2A CLINICAL EVALUATION IN CHEMOTHERAPY-RELATED PAIN, A CONDITION WITH NO APPROVED TREATMENTS AND POTENTIAL FOR FDA FAST TRACK CONSIDERATION MIAMI, FLORIDA / ACCESS NEWSWIRE / OCTOBER 24, 2025 / MIRA PHARMACEUTICALS, INC. (NASDAQ:MIRA) ("MIRA" OR THE "COMPANY"), A CLINICAL-STAGE PHARMACEUTICAL COMPANY DEVELOPING NOVEL ORAL THERAPEUTICS FOR NEUROLOGIC, NEUROPSYCHIATRIC, AND METABOLIC DISORDERS, TODAY ANNOUNCED THE INITIATION OF THE MULTIPLE ASCENDING DOSE (MAD) PORTION OF ITS ONGOING PHASE 1 CLINICAL TRIAL EVALUATING ITS LEAD ORAL CANDIDATE, KETAMIR-2, IN HEALTHY VOLUNTEERS. THE COMPANY ALSO ANNOUNCED THAT IT HAS SELECTED CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY (CIPN) - A COMMON AND DEBILITATING SIDE EFFECT OF CANCER TREATMENT - AS THE LEAD INDICATION FOR ITS PLANNED PHASE 2A CLINICAL EVALUATION.

MIRA PHARMACEUTICALS INITIATES MULTIPLE ASCENDING DOSE (MAD) PHASE 1 STUDY OF ORAL KETAMIR-2 AND SELECTS CHEMOTHERAPY-INDUCED NEUROPATHIC PAIN AS LEAD PHASE 2A INDICATION

MIRA Pharmaceuticals, Inc.

MIRA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

MIRA Pharmaceuticals, Inc.

MIRA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

MIRA